Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085621 · Präparat HOS-083163
Theoretically the metabolism of toremifene is inhibited by drugs known to inhibit the CYP3A enzyme
system which is reported to be responsible for its main metabolic pathways. Examples of such drugs
are antifungal imidazoles (ketoconazole); other antifungal agents (itraconazole, voriconazole,
posaconazole); protease inhibitors (ritonavir, nelfinavir), macrolides (clarithromycin, erythromycin,
telithromycine). Concomitant use of those drugs with toremifene should be carefully considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) nelfinavir (HOS-084520) clarithromycin (HOS-084517) erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 685a49cc637468e295a54afd3fa92b51d9800204c6cb80df9af06b295ec124ed · Zeichen 1457–1947 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110215 · Präparat HOS-093339
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors
such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole
antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such
as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib
concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of
imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a
single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering
Glivec with inhibitors of the CYP3A4 family.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) telithromycin (HOS-084523) protease (HOS-085623) indinavir (HOS-084518) lopinavir (HOS-086269) ritonavir (HOS-084521) saquinavir (HOS-084522) telaprevir (HOS-090618) nelfinavir (HOS-084520) boceprevir (HOS-090617) ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 6–7
HOS-114233 · Präparat HOS-094063
6
10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 days) by 21 % and 23 %,
respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with
ritonavir is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 21c78bafde5f8a4c6732f07d7286d0b547d28921f9c6886981bab736231d3a54 · Zeichen 1710–2022 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 9
HOS-114249 · Präparat HOS-094063
HIV Protease inhibitors
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase
plasma levels of these antiretroviral agents. Following co-administration of posaconazole oral
suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects
Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold),
respectively. Following co-administration of posaconazole oral suspension (400 mg twice daily) with
atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of
atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively. The
addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated
with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity
related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-
administration with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 2842080171ed52ad3fcc353c5e510a3b4ce13c5bf8aa7a86a01747b73a8e7529 · Zeichen 11339–12374 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-114284 · Präparat HOS-094063
Fosamprenavir
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma
concentrations. If concomitant administration is required, close monitoring for breakthrough fungal
infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x
10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %,
respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with
ritonavir is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosamprenavir (HOS-086182) lead (HOS-085592) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1366–1966 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-114300 · Präparat HOS-094063
HIV Protease inhibitors
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase
plasma levels of these antiretroviral agents. Following co-administration of posaconazole oral
suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects
Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold),
respectively. Following co-administration of posaconazole oral suspension (400 mg twice daily) with
atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of
atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively. The
addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated
with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) atazanavir (HOS-086180) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 934372885ff3f155bd43eb277bfb9a79b117d084b2845df6a5eba776c709f202 · Zeichen 10758–11670 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 47
HOS-114339 · Präparat HOS-094063
Fosamprenavir
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma
concentrations. If concomitant administration is required, close monitoring for breakthrough fungal
infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x
10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %,
respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with
ritonavir is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) fosamprenavir (HOS-086182) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1768–2368 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 49
HOS-114353 · Präparat HOS-094063
HIV Protease inhibitors
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase
plasma levels of these antiretroviral agents. Following co-administration of posaconazole oral
suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects
Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold),
respectively. Following co-administration of posaconazole oral suspension (400 mg twice daily) with
atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of
atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively. The
addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated
with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity
related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-
administration with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) ritonavir (HOS-084521) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 2842080171ed52ad3fcc353c5e510a3b4ce13c5bf8aa7a86a01747b73a8e7529 · Zeichen 10283–11318 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 71
HOS-114391 · Präparat HOS-094063
Fosamprenavir
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma
concentrations. If concomitant administration is required, close monitoring for breakthrough fungal
infections is recommended. Repeat dose administration of fosamprenavir (700 mg twice daily x
10 days) decreased the Cmax and AUC of posaconazole oral suspension (200 mg once daily on the
1st day, 200 mg twice daily on the 2nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %,
respectively. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with
ritonavir is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosamprenavir (HOS-086182) lead (HOS-085592) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b5bbce510ddb458a7317b9f10c586066a3d42da77e8f20dcec5a31067ba748a9 · Zeichen 1425–2025 im Abschnitt
Wechselwirkungen · Noxafil
Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 73
HOS-114406 · Präparat HOS-094063
HIV Protease inhibitors
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase
plasma levels of these antiretroviral agents. Following co-administration of posaconazole oral
suspension (400 mg twice daily) with atazanavir (300 mg once daily) for 7 days in healthy subjects
Cmax and AUC of atazanavir increased by an average of 2.6-fold and 3.7-fold (range 1.2 to 26-fold),
respectively. Following co-administration of posaconazole oral suspension (400 mg twice daily) with
atazanavir and ritonavir (300/100 mg once daily) for 7 days in healthy subjects Cmax and AUC of
atazanavir increased by an average of 1.5-fold and 2.5-fold (range 0.9 to 4.1-fold), respectively. The
addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated
with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity
related to antiretroviral agents that are substrates of CYP3A4 is recommended during
co-administration with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) atazanavir (HOS-086180) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage b627da78d8284889606d449b498791a8f86a9e8f2e8c544e58dc49f424088b1e · Zeichen 10813–11847 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17–18
HOS-116378 · Präparat HOS-094447
17
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and
considerations PREZISTA dose adjustment of metformin is
co-administered with cobicistat is recommended in patients who are
expected to increase metformin plasma taking PREZISTA co-administered
concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for PREZISTA
co-administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended. When
Itraconazole and posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): metformin (HOS-091032) cobicistat (HOS-088111) ritonavir (HOS-084521) domperidone (HOS-114656) voriconazole (HOS-084524) fluconazole (HOS-087945) isavuconazole (HOS-085186) itraconazole (HOS-084516) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 5307db9d59d8efdd7ae524944aa157f963cc375ad8c53e1296ceb7c11992bc47 · Zeichen 40055–42401 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116522 · Präparat HOS-094447
Concomitant use of PREZISTA Clinical monitoring is
co-administered with low dose ritonavir recommended when
and these antidepressants may increase co-administering PREZISTA with
concentrations of the antidepressant. low dose ritonavir with these
(CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
Amitriptyline may be needed.
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with PREZISTA
(induction of CYP450 enzymes) co-administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the
use of voriconazole.
Fluconazole Not studied. PREZISTA may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) nortriptyline (HOS-086245) trazodone (HOS-086251) domperidone (HOS-114656) voriconazole (HOS-084524) fluconazole (HOS-087945) isavuconazole (HOS-085186) itraconazole (HOS-084516) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 22f4e74ad4f26762902abfc0033ac15b80ded8bd1a23d2f6a966a8c972097288 · Zeichen 30842–32867 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99–100
HOS-116613 · Präparat HOS-094447
99
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with boosted
(induction of CYP450 enzymes) PREZISTA unless an assessment
of the benefit/risk ratio justifies the
Concentrations of voriconazole may use of voriconazole.
increase or decrease when
co-administered with PREZISTA
co-administered with cobicistat.
(inhibition of CYP450 enzymes)
Fluconazole Not studied. Boosted PREZISTA may Caution is warranted and clinical
Isavuconazole increase antifungal plasma concentrations monitoring is recommended.
Itraconazole and posaconazole, isavuconazole, When co-administration is
Posaconazole itraconazole or fluconazole may increase required the daily dose of
darunavir concentrations. itraconazole should not exceed
(CYP3A and/or P-gp inhibition) 200 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): domperidone (HOS-114656) voriconazole (HOS-084524) ritonavir (HOS-084521) cobicistat (HOS-088111) fluconazole (HOS-087945) isavuconazole (HOS-085186) itraconazole (HOS-084516) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 13c8fc0fe58788a9eb15a4ab6e0e9fb34c04f3bc6ed970d671cb11cef0f8bb26 · Zeichen 40236–41872 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) telithromycin (HOS-084523) troleandomycin (HOS-090575) clarithromycin (HOS-084517) josamycin (HOS-113844) protease (HOS-085623) ritonavir (HOS-084521) nelfinavir (HOS-084520) saquinavir (HOS-084522) telaprevir (HOS-090618) boceprevir (HOS-090617) ombitasvir (HOS-110300) paritaprevir (HOS-110301) dasabuvir (HOS-110302) nefazodone (HOS-084519) cobicistat (HOS-088111) idelalisib (HOS-116811) ceritinib (HOS-086215) erythromycin (HOS-084514) fluconazole (HOS-087945) isavuconazole (HOS-085186) clotrimazole (HOS-090574) miconazole (HOS-115630) azithromycin (HOS-088112) calcium (HOS-085615) nifedipine (HOS-086289) nicardipine (HOS-090619) diltiazem (HOS-086288) verapamil (HOS-090602) amiodarone (HOS-085596) danazol (HOS-085473) lansoprazole (HOS-085166) omeprazole (HOS-085912) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) letermovir (HOS-090621) tyrosine (HOS-108875) nilotinib (HOS-086218) crizotinib (HOS-116818) imatinib (HOS-110212)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-120043 · Präparat HOS-095079
CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a
day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in
mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an
increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving
concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole,
voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong
inhibitors of both CYP3A4 and P-gp (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ketoconazole (HOS-084513) ritonavir (HOS-084521) lead (HOS-085592) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 97fb88bb60a56df48aee5a4e53e25036bdc5742ddee482536bdc179f973ed210 · Zeichen 0–663 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 123
HOS-120169 · Präparat HOS-095079
CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a
day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in
mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an
increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving
concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole,
voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong
inhibitors of both CYP3A4 and P-gp (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) ritonavir (HOS-084521) lead (HOS-085592) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 97fb88bb60a56df48aee5a4e53e25036bdc5742ddee482536bdc179f973ed210 · Zeichen 0–663 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 1 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 148
HOS-120201 · Präparat HOS-095079
CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a
day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in
mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an
increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving
concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole,
voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong
inhibitors of both CYP3A4 and P-gp (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) ritonavir (HOS-084521) lead (HOS-085592) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 97fb88bb60a56df48aee5a4e53e25036bdc5742ddee482536bdc179f973ed210 · Zeichen 223–886 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-124376 · Präparat HOS-095863
The use of apixaban is not recommended in patients receiving concomitant systemic treatment with
strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,
itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 66b4ddafefbf922d3e024d9cb2c668e01214dcd7dc8e71059564fe34b9fced35 · Zeichen 237–534 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44–45
HOS-124433 · Präparat HOS-095863
44
The use of apixaban is not recommended in patients receiving concomitant systemic treatment with
strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,
itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 2e25a3e13f5d96eb21917d5a5bf5a92df61d2c18ec8ada3955e5651b0ad5e753 · Zeichen 289–590 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 0.15 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 74
HOS-124484 · Präparat HOS-095863
The use of apixaban is not recommended in patients receiving concomitant systemic treatment with
strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,
itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 66b4ddafefbf922d3e024d9cb2c668e01214dcd7dc8e71059564fe34b9fced35 · Zeichen 450–747 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.